TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00110617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox (ICL670)
Description: Deferasirox was provided in 125 mg, 250 mg, and 500 mg dispersible tablets and was administered orally at an initial dose of 20 mg/kg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox (ICL670)
Description: Deferasirox was provided in 125 mg, 250 mg, and 500 mg dispersible tablets and was administered orally at an initial dose of 20 mg/kg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferoxamine (DFO)
Description: Deferoxamine was supplied in vials of 500 mg and 2000 mg administered subcutaneously for a weekly dose of 175 mg/kg.
Study: NCT02378168

Intervention type: OTHER
Intervention: no intervention; retrospective study
Study: NCT01093352

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alveolar-decortication.
Description: Following surgical exposure of the impacted tooth, the surgeon will prepare small holes (perforations) and/or grooves in the cortical bone surrounding the exposed tooth as well as in the buccal bone.
Study: NCT01823848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium phosphate enema
Description: Rectally administered medication to treat constipation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium phosphate enema
Description: Rectally administered medication to treat constipation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium phosphate enema
Description: Rectally administered medication to treat constipation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline enema
Description: Rectally administered medication to treat constipation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline enema
Description: Rectally administered medication to treat constipation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline enema
Description: Rectally administered medication to treat constipation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mineral oil enema
Description: Mineral oil enema administered to treat constipation. 66ml per rectum

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mineral oil enema
Description: Mineral oil enema administered to treat constipation. 66ml per rectum

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mineral oil enema
Description: Mineral oil enema administered to treat constipation. 66ml per rectum
Study: NCT01774565

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fully Automated Closed-Loop Insulin Delivery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional insulin therapy
Study: NCT00586807

Intervention type: OTHER
Group type: OTHER
Intervention: Stable amino acid isotopes
Description: Stable amino acid isotopes given per IV, dose based on weight and given over the length of the study visit.
Study: NCT03623776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS001
Description: JS001 was given 240 mg i.v. infusion on Day 1 of each 21-day cycle for 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS001
Description: JS001 was given 240 mg i.v. infusion on Day 1 of each 21-day cycle for 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Subjects receive pemetrexed of 500 mg/m\^2 administered as IV infusion on Day 1 of each 21-day cycle for 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Subjects receive carboplatin at the AUC of 5 administered as IV infusion on Day 1 of each 21-day cycle for 3 cycles.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic Surgery
Description: Surgery will be performed at least 21 days after the last dose of neoadjuvant therapy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic Surgery
Description: Surgery will be performed at least 21 days after the last dose of neoadjuvant therapy.
Study: NCT03643770

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Upper extremity training/Armeo Spring
Description: Armeo Spring is a gravity support system based on an ergonomic arm exoskeleton with integrated springs.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Upper extremity training/Armeo Spring
Description: Armeo Spring is a gravity support system based on an ergonomic arm exoskeleton with integrated springs.
Study: NCT03590847

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intermittent Fasting
Description: Study participants will be asked to fast for a target of 16 hours per day for a period of 4 weeks. Participants will be allowed to consume calorie-free beverages, water, tea, black coffee or sugar-free gum during the fasting period. Participants will be asked to record the time of first and final food/drink consumption each day.
Study: NCT02597283

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biguard sirolimus-eluting bifurcation stent system
Description: PCI with Biguard sirolimus-eluting bifurcation stent system

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus-eluting stent system
Description: PCI with sirolimus-eluting stent system
Study: NCT00769782

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: All patients undergo suegery to achieve macroscopic complete resection within 28 days after enrollment (including enrollment day). As long as tumor free margin is ensured, all resection margin distances and all surgical procedure are accepted. Surgical treatment in this study excludes the following, radiofrequency ablation (RFA) without resection of liver only or microwave coagulation therapy (MCT) only; for RFA or MCT is used as additional treatment under judgment of primary physician for new liver tumor which comfirmed during surgery in different parts of liver except portion scheduled for resection, RFA and MCT are included. After histological curative resection, patients are observed without treatment until comfirming recurrence. Patients with incomplete tumor removal are withdrawn from protcol treatment and receive imatinib treatment, 400 mg/day orally. For reccurrence is comfirmed, patients receive imatinib treatment, 400 mg/day orally.
Study: NCT01972542

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Oral fat tolerance test

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral fat tolerance test

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral fat tolerance test
Study: NCT00395200

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MSC Treatment
Description: Intravenous administration of up to 2x10\^6 autologous MSCs per kg
Study: NCT00640822

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcipotriol plus hydrocortisone ointment vehicle
Description: Once daily application for up to 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacalcitol Ointment
Description: Once daily application for up to 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcipotriol plus hydrocortisone ointment
Description: Once daily application for up to 8 weeks
Study: NCT02476734

Intervention type: OTHER
Intervention: There is no intervention
Description: Subjects undergo FDG-PET CT scans in order to determine lesional FDG intake and changes in lesional FDG uptake.

Intervention type: OTHER
Intervention: There is no intervention
Description: Subjects undergo FDG-PET CT scans in order to determine lesional FDG intake and changes in lesional FDG uptake.
Study: NCT03855124

Intervention type: DEVICE
Intervention: Posture shirt
Description: Posture shirts are designed, and marketed to the general public and health service providers to improve posture and consequently alter muscle actitity, reduce musculoskeletal pain and discomfort.
Study: NCT04514770

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: rupture of membrane early and late

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: rupture of membrane early and late
Study: NCT00787670

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Support and Education
Description: The subjects will attend three educational/social support sessions for 1 year after enrollment. The educational sessions include informational sessions on diet/nutrition and exercise. These sessions are informational and do not teach behavioral self-regulation skills.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: gastric bypass surgery
Description: gastric bypass surgery to induce weight loss in obese patients with type 2 diabetes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tissue Control Group
Description: During the abdominal surgery we would like to take 5 ml blood from the IV line and small pea-sized samples of the fat tissue just under the skin and around the stomach area. These samples will be stored so that we can compare these tissue with other patients.
Study: NCT02666365

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bolus infusion of Cefazolin
Description: Subjects in the bolus infusion arm of the study will receive bolus infusions of cefazolin throughout the surgical procedure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous infusion of Cefazolin
Description: Subjects in the continuous infusion arm of the study will receive a continuous infusion of the cefazolin throughout the surgical procedure
Study: NCT03340766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Up to 2 cycles of blinatumomab may be given, where cycle 1 lasts 8 weeks, and cycle 2 lasts 28 days. The treatment is given as a continuous intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Up to 2 cycles of blinatumomab may be given, where cycle 1 lasts 8 weeks, and cycle 2 lasts 28 days. The treatment is given as a continuous intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Up to 2 cycles of blinatumomab may be given, where cycle 1 lasts 8 weeks, and cycle 2 lasts 28 days. The treatment is given as a continuous intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Up to 2 cycles of blinatumomab may be given, where cycle 1 lasts 8 weeks, and cycle 2 lasts 28 days. The treatment is given as a continuous intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: One cycle of pembrolizumab is a 200 mg IV injection lasting 30 minutes. One cycle will be given every 3 weeks until disease progression, or for a maximum of 35 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: One cycle of pembrolizumab is a 200 mg IV injection lasting 30 minutes. One cycle will be given every 3 weeks until disease progression, or for a maximum of 35 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: One cycle of pembrolizumab is a 200 mg IV injection lasting 30 minutes. One cycle will be given every 3 weeks until disease progression, or for a maximum of 35 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: One cycle of pembrolizumab is a 200 mg IV injection lasting 30 minutes. One cycle will be given every 3 weeks until disease progression, or for a maximum of 35 cycles.
Study: NCT00877500

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Description: Given IV
Study: NCT03772119

Intervention type: PROCEDURE
Intervention: Surgical resection
Description: Surgical resection of hemivertebra
Study: NCT03558867

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin + Healthy diet
Description: Metformin (1500 mg/d, Extended Release) + Healthy, low fat diet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin + Personalized diet
Description: Metformin (1500 mg/d, Extended Release) + Algorithm-based personalized diet
Study: NCT06021717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine-Morphine
Description: PCA ketamine (Ketamine HCl, Pfizer Inc., US) 0.5 mg plus morphine 0.5 mg ml-1 (ratio 1:1)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: PCA morphine (Pfizer Inc., US) 1 mg ml-1
Study: NCT01962493

Intervention type: OTHER
Group type: OTHER
Intervention: Sodium bicarbonate/ Sodium Fluoride
Description: Toothpaste containing sodium bicarbonate and sodium fluoride as cosmetic

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sodium fluoride
Description: Toothpaste containing sodium fluoride as cosmetic

Intervention type: DRUG
Group type: OTHER
Intervention: Chlorhexidine digluconate
Description: Mouthwash containing chlorhexidine digluconate
Study: NCT04428502

Intervention type: DRUG
Intervention: Enbrel
Description: As provided in real world practice
Study: NCT04416828

Intervention type: DEVICE
Intervention: Portable wireless ultrasonography devices
Description: Patients with suspected ganglion cyst of the wrist or hand receive portable wireless ultrasound imaging

Intervention type: DEVICE
Intervention: Cart-based ultrasonography device
Description: Patients with suspected ganglion cyst of the wrist or hand receive conventional cart-based ultrasound imaging
Study: NCT01602198

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exelon [rivastigmine] transdermal patch
Description: Exelon patch 1/day for six months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo transdermal patch
Description: Placebo transdermal patch 1/day for 6 months
Study: NCT03208257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol
Description: Esmolol hydrochloride infusion
Study: NCT02803645

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample
Study: NCT04500691

Intervention type: OTHER
Intervention: pain intensity reporting
Description: pain intensity reporting
Study: NCT01677403

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tobramycin
Description: Nebulised 80mg twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Nebulised 5mls 0.9% Saline twice daily
Study: NCT02657356

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bardoxolone methyl capsules
Study: NCT03768882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol
Description: 1000 mg of paracetamol (parol 10mg/ml Mefar, Turkey) intravenous (IV) was given 102 patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexketoprofen
Description: Second group: dexketoprofen 50 MG (Arveles ampoule -İE Ulagay -Menarini,Turkey) intravenous (IV) was given 98 patients
Study: NCT02902380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine group
Description: dexmedetomidine infusion (0.4 mcg/kg/h) from immediately after anesthetic induction to end of surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: 0.9% saline infusion
Study: NCT00628745

Intervention type: OTHER
Intervention: None. Observational Study.
Study: NCT03470909

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Skin-Sparing Mastectomy (SSM)
Description: For patients undergoing SSM, 10 points of interest in radial localization have been selected for investigation of the presence of residual breast tissue.~The points are located under the remaining skin envelope and will be investigated by performing small biopsies with a cervical biopsy forceps.~Additionally, the distance between the surface of the specimen and the glandular tissue will be explored at five points at the base of the removed breast.~These histological sections will be radially oriented.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Nipple-Sparing Mastectomy (NSM)
Description: For patients undergoing NSM, 14 points of interest in radial localization have been selected for investigation of the presence of residual breast tissue, i.e. comparing to SSM, 4 additional biopsies will be taken behind the peripheral part of the areola.~The points are located under the remaining skin envelope and will be investigated by performing small biopsies with a cervical biopsy forceps.~Additionally, the distance between the surface of the specimen and the glandular tissue will be explored at five points at the base of the removed breast.~These histological sections will be radially oriented.
Study: NCT04403373

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Waitlist control
Description: waitlist control

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate-intensity walking exercise
Description: walking exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vigorous-intensity walking exercise
Description: walking exercise
Study: NCT00970931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorthalidone plus amiloride
Description: Oral Chlorthalidone 12.5 mg plus amiloride 2.5 mg, once a day for 18 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Oral placebo once a day, for 18 months
Study: NCT01538589

Intervention type: DRUG
Intervention: insulin aspart
Description: Prescribed by the physicians as a result of normal clinical practice
Study: NCT03124173

Intervention type: OTHER
Group type: OTHER
Intervention: Training session
Description: The subjects will be trained to realize several versions of a learning task of conditional visuo-motor associations.

Intervention type: OTHER
Group type: OTHER
Intervention: First fMRI session
Description: In this session (involving a condition specific to man and a condition that we are certain to obtain in the monkey), subjects will have to learn by trial and error during successive trials, the conditional associations between three abstract stimuli and three Manual responses (3 MRI-compatible mouse buttons).

Intervention type: OTHER
Group type: OTHER
Intervention: Second fMRI session
Description: In this session (involving a condition specific to man and a condition that we are almost certain to obtain in monkeys), subjects will have to learn by trial and error during successive trials, the conditional associations between three abstract stimuli and Three orofacial responses (3 movements of the mouth).

Intervention type: OTHER
Group type: OTHER
Intervention: Third session of fMRI
Description: In this session (involving a human-specific condition and a condition we hope to achieve in the monkey), subjects will have to learn by trial-error in successive trials, conditional associations between three abstract stimuli and three verbal or Vocals.
Study: NCT02588352

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Salt tablet
Description: Subjects will be given salt tablets and instructed to take 4 grams of sale three times a day (total of 12 grams of salt/day) for one week
Study: NCT04188496

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary Function Test group
Description: The interventional group received the same conventional Chest physiotherapy Techniques for 30 minutes followed by 10 minutes rest. The patients then received additional 15 minutes protocol of thoracic joint mobilization

Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: received conventional Chest physiotherapy Techniques for 30 minutes (including deep breathing, diaphragmatic breathing exercises, Self-stretching exercises for accessory respiratory muscles, Respiratory Resistance training by incentive spirometer) followed by 10 min rest.
Study: NCT01731860

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Additional PET Scan
Description: Additional PET Scan with no additional radiopharmaceutical administration.
Study: NCT00294320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldara (Imiquimod)
Description: 250mg of Imiquimod cream for application once daily 3 times per week.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle cream
Description: 250mg vehicle cream for application once daily 3 times per week.
Study: NCT02387788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKB-9778
Description: Phase 2a open-label study to assess the efficacy and safety of subcutaneous 15mg AKB-9778 administered twice daily for 84 days in subjects with macular edema due to RVO.
Study: NCT03667170

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KN035
Description: subcutaneous injection
Study: NCT04254263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyrotinib
Description: pyrotinib 400 mg, orally once daily for one year
Study: NCT04783792

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ascorbic acid / phytochemical supplement
Description: Ascorbic acid / phytochemical supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ascorbic acid
Description: Ascorbic acid
Study: NCT03648086

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intestinal microbiota transplantation
Description: Participants in Exprerimental group take 6 times IMT with 2-week intervals
Study: NCT04171986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mecapegfilgrastim
Description: Mecapegfilgrastim; 6 mg, d7, q3w, total 2 cycles.
Study: NCT04034199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Denosumab is a human monoclonal antibody against receptor activator of nuclear factor kappa-B ligand (RANKL) and its use is associated with a reduced risk of vertebral, non-vertebral and hip fracture in post-menopausal women. RANKL plays a crucial role in the pathogenesis of glucocorticoid-induced osteoporosis (GIOP). Its production is increased by GC, resulting in stimulated osteoprotegerin ligand production and increased bone resorption. Recent randomized controlled trial from Saag et al have shown that denosumab is more efficacious than risedronate in the improvement of BMD in GIOP patients. Denosumab has been confirmed efficacious in GIOP patients but its efficacy in high-risk osteopenia patients are not well studied. It is given subcutaneously at 60mg every 6 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic Acid
Description: Zoledronic acid belongs to bisphosphonates and is licensed for the treatment of GIOP and 2 RCTs found zoledronic acid has superior efficacy in improvement in BMD at lumbar spine or femoral neck at 12 months when compared to risedronate. It is given intravenously every year at a dosage of 5mg.
Study: NCT04048720

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Nurture Intervention
Description: The mother-child pair will be asked to talk and play with each other as the pair customarily does. If the child becomes restless and dysregulated, the mother will be coached by the Nurture Specialist to bring the child back into a calm state through sustained physical contact, comforting touch, soothing words and eye contact. Each dyad will be offered eight group FNI sessions.